Sen Kwek S., Watanabe S., Chan K. R., Ong E. Z., Tan H. C., Ng W. C., Nguyen M. T. X., Gan E. S., Zhang S. L., Chan K. W. K., Tan J. H., Sessions O. M., Manuel M., Pompon Julien, Chua C., Hazirah S., Tryggvason K., Vasudevan S. G., Ooi E. E. (2018). A systematic approach to the development of a safe live attenuated Zika vaccine. Nature Communications, 9, p. art. 1031 [13 p.]. ISSN 2041-1723.
Titre du document
A systematic approach to the development of a safe live attenuated Zika vaccine
Année de publication
2018
Auteurs
Sen Kwek S., Watanabe S., Chan K. R., Ong E. Z., Tan H. C., Ng W. C., Nguyen M. T. X., Gan E. S., Zhang S. L., Chan K. W. K., Tan J. H., Sessions O. M., Manuel M., Pompon Julien, Chua C., Hazirah S., Tryggvason K., Vasudevan S. G., Ooi E. E.
Source
Nature Communications, 2018,
9, p. art. 1031 [13 p.] ISSN 2041-1723
Zika virus (ZIKV) is a flavivirus that can cause congenital disease and requires development of an effective long-term preventative strategy. A replicative ZIKV vaccine with properties similar to the yellow fever 17D (YF17D) live-attenuated vaccine (LAV) would be advantageous, as a single dose of YF17D produces lifelong immunity. However, a replicative ZIKV vaccine must also be safe from causing persistent organ infections. Here we report an approach to ZIKV LAV development. We identify a ZIKV variant that produces small plaques due to interferon (IFN)-restricted viral propagation and displays attenuated infection of endothelial cells. We show that these properties collectively reduce the risk of organ infections and vertical transmission in a mouse model but remain sufficiently immunogenic to prevent wild-type ZIKV infection. Our findings suggest a strategy for the development of a safe but efficacious ZIKV LAV.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Localisation
Fonds IRD [F B010072485]
Identifiant IRD
fdi:010072485
